ProCE Banner Activity

CE / CME

Updates on the Management of Patients With Lymphomas During the COVID-19 Pandemic

Multimedia
Watch this interactive webcast of a live CCO webinar tailored to the multidisciplinary oncology team to gain expert perspectives on the care of patients with lymphomas during the COVID-19 pandemic.

Pharmacists: 0.75 contact hour (0.075 CEUs)

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Nurses: 0.75 Nursing contact hour

Released: October 19, 2021

Expiration: October 18, 2022

No longer available for credit.

Share

Faculty

John N. Allan

John N. Allan, MD

Associate Professor of Clinical Medicine
Division of Hematology and Medical Oncology
Weill Cornell Medicine
New York, New York

Sandra E. Kurtin

Sandra E. Kurtin, PhD, ANP-C, AOCN

Director, Advanced Practice and Clinical Integration
The University of Arizona Cancer Center
Assistant Professor, Clinical Medicine
Adjunct Clinical Professor, Nursing
The University of Arizona
Tucson, Arizona

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Pharmacyclics AbbVie Company Janssen Biotech admin Janssen Sci

Target Audience

This educational program is intended for hematologists, oncologists, nurses, pharmacists, and advanced practitioners in hematology/oncology who care for patients with MCL, MZL, CLL/SLL, or WM receiving targeted therapeutics as part of in-home care.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Provide appropriate management strategies for patients with MCL, MZL, CLL/SLL, and WM receiving in-home care with targeted therapies or immunotherapies during the COVID-19 pandemic
  • Select or modify treatment based on the available clinical data, guidelines, and expert recommendations to reduce office visits and maintain efficacy
  • Integrate telemedicine for routine follow-up visits, as appropriate
  • Manage adverse events associated with treatment approaches for MCL, MZL, CLL/SLL, and WM receiving in-home care with targeted therapies or immunotherapies to ensure treatment compliance as well as improved clinical outcomes and quality of life
  • Provide counsel to patients and caregivers based on best practices for infection control

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

John N. Allan, MD

Associate Professor of Clinical Medicine
Division of Hematology and Medical Oncology
Weill Cornell Medicine
New York, New York

John Allan, MD, has disclosed that he has received consulting fees from AbbVie, ADC Therapeutics, BeiGene, Epizyme, Genentech, Janssen, Pharmacyclics, and TG Therapeutics; funds for research support from Genentech, Janssen, and TG Therapeutics; and fees for non-CME/CE services from AbbVie, BeiGene, Janssen, and Pharmacyclics.

Sandra E. Kurtin, PhD, ANP-C, AOCN

Director, Advanced Practice and Clinical Integration
The University of Arizona Cancer Center
Assistant Professor, Clinical Medicine
Adjunct Clinical Professor, Nursing
The University of Arizona
Tucson, Arizona

Sandra E. Kurtin, PhD, ANP-C, AOCN, has disclosed that she has received consulting fees from AbbVie, Amgen, Bristol-Myers Squibb, Epizyme, Incyte, and Pharmacyclics.

Staff Disclosure

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.

Jason J. Everly, PharmD

Jason Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Krista Marcello,

Associate Managing Editor

Krista Marcello has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hours.

Credit Designation

CCO designates this continuing education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-21-223-H01-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 19, 2021, through October 18, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to provide a comprehensive, agile, and highly accessible educational curriculum designed to improve oncology healthcare professionals’ competence in providing effective personalized care for patients with MCL, MZL, CLL/SLL, and WM receiving in-home care with targeted therapies or immunotherapies during the COVID-19 pandemic.